Varian, a Siemens Healthineers company, is highlighting that the first patient has been treated in the Radiate-VT clinical trial at Washington University School of Medicine in St. Louis, MO.
The trial is intended to evaluate the safety of cardiac radioablation compared with catheter ablation for patients with high-risk, refractory ventricular tachycardia (VT); the treatment was delivered with Varian's cardiac radioablation system, which received breakthrough device designation from the U.S. Food and Drug Administration in May 2021.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
